nodes	percent_of_prediction	percent_of_DWPC	metapath
Naltrexone—ABCB1—melanoma	0.541	1	CbGaD
Naltrexone—Naloxone—TLR4—melanoma	0.00389	0.683	CrCbGaD
Naltrexone—Sinusitis—Temozolomide—melanoma	0.000746	0.00267	CcSEcCtD
Naltrexone—Hallucination—Carmustine—melanoma	0.000735	0.00263	CcSEcCtD
Naltrexone—Hot flush—Docetaxel—melanoma	0.000734	0.00262	CcSEcCtD
Naltrexone—Hypersensitivity—Vemurafenib—melanoma	0.000732	0.00262	CcSEcCtD
Naltrexone—Menopausal symptoms—Docetaxel—melanoma	0.000728	0.0026	CcSEcCtD
Naltrexone—Connective tissue disorder—Carmustine—melanoma	0.000726	0.0026	CcSEcCtD
Naltrexone—Atrial fibrillation—Docetaxel—melanoma	0.000725	0.00259	CcSEcCtD
Naltrexone—Hepatitis—Temozolomide—melanoma	0.000714	0.00255	CcSEcCtD
Naltrexone—Asthenia—Vemurafenib—melanoma	0.000712	0.00255	CcSEcCtD
Naltrexone—Hallucination—Temozolomide—melanoma	0.000711	0.00254	CcSEcCtD
Naltrexone—Pharyngitis—Temozolomide—melanoma	0.000709	0.00253	CcSEcCtD
Naltrexone—Chills—Dactinomycin—melanoma	0.000709	0.00253	CcSEcCtD
Naltrexone—Pruritus—Vemurafenib—melanoma	0.000703	0.00251	CcSEcCtD
Naltrexone—Connective tissue disorder—Temozolomide—melanoma	0.000702	0.00251	CcSEcCtD
Naltrexone—Lethargy—Docetaxel—melanoma	0.000701	0.0025	CcSEcCtD
Naltrexone—Alopecia—Dactinomycin—melanoma	0.000698	0.00249	CcSEcCtD
Naltrexone—Eye disorder—Carmustine—melanoma	0.000691	0.00247	CcSEcCtD
Naltrexone—Pain in extremity—Docetaxel—melanoma	0.000687	0.00245	CcSEcCtD
Naltrexone—Gastrointestinal haemorrhage—Docetaxel—melanoma	0.000687	0.00245	CcSEcCtD
Naltrexone—Ill-defined disorder—Bleomycin—melanoma	0.000684	0.00244	CcSEcCtD
Naltrexone—Diarrhoea—Vemurafenib—melanoma	0.000679	0.00243	CcSEcCtD
Naltrexone—Migraine—Docetaxel—melanoma	0.000676	0.00242	CcSEcCtD
Naltrexone—Eye disorder—Temozolomide—melanoma	0.000668	0.00239	CcSEcCtD
Naltrexone—Tinnitus—Temozolomide—melanoma	0.000666	0.00238	CcSEcCtD
Naltrexone—Malaise—Bleomycin—melanoma	0.000665	0.00238	CcSEcCtD
Naltrexone—Cardiac disorder—Temozolomide—melanoma	0.000663	0.00237	CcSEcCtD
Naltrexone—Dizziness—Vemurafenib—melanoma	0.000657	0.00235	CcSEcCtD
Naltrexone—Alopecia—Carmustine—melanoma	0.000653	0.00233	CcSEcCtD
Naltrexone—Angiopathy—Temozolomide—melanoma	0.000648	0.00232	CcSEcCtD
Naltrexone—Mental disorder—Carmustine—melanoma	0.000648	0.00231	CcSEcCtD
Naltrexone—Immune system disorder—Temozolomide—melanoma	0.000645	0.00231	CcSEcCtD
Naltrexone—Mediastinal disorder—Temozolomide—melanoma	0.000644	0.0023	CcSEcCtD
Naltrexone—Malnutrition—Carmustine—melanoma	0.000643	0.0023	CcSEcCtD
Naltrexone—Cough—Bleomycin—melanoma	0.000643	0.0023	CcSEcCtD
Naltrexone—Chills—Temozolomide—melanoma	0.000641	0.00229	CcSEcCtD
Naltrexone—Dehydration—Docetaxel—melanoma	0.000639	0.00228	CcSEcCtD
Naltrexone—Ill-defined disorder—Dactinomycin—melanoma	0.000638	0.00228	CcSEcCtD
Naltrexone—Vomiting—Vemurafenib—melanoma	0.000631	0.00226	CcSEcCtD
Naltrexone—Alopecia—Temozolomide—melanoma	0.000631	0.00226	CcSEcCtD
Naltrexone—Myalgia—Bleomycin—melanoma	0.000628	0.00224	CcSEcCtD
Naltrexone—Chest pain—Bleomycin—melanoma	0.000628	0.00224	CcSEcCtD
Naltrexone—Abdominal pain upper—Docetaxel—melanoma	0.000627	0.00224	CcSEcCtD
Naltrexone—Rash—Vemurafenib—melanoma	0.000626	0.00224	CcSEcCtD
Naltrexone—Mental disorder—Temozolomide—melanoma	0.000626	0.00224	CcSEcCtD
Naltrexone—Dermatitis—Vemurafenib—melanoma	0.000625	0.00224	CcSEcCtD
Naltrexone—Back pain—Carmustine—melanoma	0.000622	0.00222	CcSEcCtD
Naltrexone—Headache—Vemurafenib—melanoma	0.000622	0.00222	CcSEcCtD
Naltrexone—Malnutrition—Temozolomide—melanoma	0.000622	0.00222	CcSEcCtD
Naltrexone—Discomfort—Bleomycin—melanoma	0.00062	0.00222	CcSEcCtD
Naltrexone—Malaise—Dactinomycin—melanoma	0.00062	0.00222	CcSEcCtD
Naltrexone—Cramp muscle—Docetaxel—melanoma	0.000618	0.00221	CcSEcCtD
Naltrexone—Aspartate aminotransferase increased—Docetaxel—melanoma	0.000618	0.00221	CcSEcCtD
Naltrexone—Nasopharyngitis—Docetaxel—melanoma	0.000614	0.00219	CcSEcCtD
Naltrexone—Dysgeusia—Temozolomide—melanoma	0.000609	0.00218	CcSEcCtD
Naltrexone—Confusional state—Bleomycin—melanoma	0.000607	0.00217	CcSEcCtD
Naltrexone—Vision blurred—Carmustine—melanoma	0.000606	0.00217	CcSEcCtD
Naltrexone—Alanine aminotransferase increased—Docetaxel—melanoma	0.000606	0.00216	CcSEcCtD
Naltrexone—Tremor—Carmustine—melanoma	0.000603	0.00216	CcSEcCtD
Naltrexone—Oedema—Bleomycin—melanoma	0.000602	0.00215	CcSEcCtD
Naltrexone—Anaphylactic shock—Bleomycin—melanoma	0.000602	0.00215	CcSEcCtD
Naltrexone—Back pain—Temozolomide—melanoma	0.000601	0.00215	CcSEcCtD
Naltrexone—Infection—Bleomycin—melanoma	0.000598	0.00214	CcSEcCtD
Naltrexone—Agitation—Carmustine—melanoma	0.000591	0.00211	CcSEcCtD
Naltrexone—Nausea—Vemurafenib—melanoma	0.00059	0.00211	CcSEcCtD
Naltrexone—Vision blurred—Temozolomide—melanoma	0.000586	0.00209	CcSEcCtD
Naltrexone—Myalgia—Dactinomycin—melanoma	0.000585	0.00209	CcSEcCtD
Naltrexone—Tremor—Temozolomide—melanoma	0.000583	0.00208	CcSEcCtD
Naltrexone—Discomfort—Dactinomycin—melanoma	0.000578	0.00207	CcSEcCtD
Naltrexone—Angina pectoris—Docetaxel—melanoma	0.000578	0.00207	CcSEcCtD
Naltrexone—Ill-defined disorder—Temozolomide—melanoma	0.000577	0.00206	CcSEcCtD
Naltrexone—Anorexia—Bleomycin—melanoma	0.000573	0.00205	CcSEcCtD
Naltrexone—Agitation—Temozolomide—melanoma	0.000571	0.00204	CcSEcCtD
Naltrexone—Angioedema—Temozolomide—melanoma	0.000568	0.00203	CcSEcCtD
Naltrexone—Oedema—Dactinomycin—melanoma	0.000561	0.00201	CcSEcCtD
Naltrexone—Malaise—Temozolomide—melanoma	0.000561	0.002	CcSEcCtD
Naltrexone—Convulsion—Carmustine—melanoma	0.000557	0.00199	CcSEcCtD
Naltrexone—Infection—Dactinomycin—melanoma	0.000557	0.00199	CcSEcCtD
Naltrexone—Hypertension—Carmustine—melanoma	0.000556	0.00199	CcSEcCtD
Naltrexone—Palpitations—Temozolomide—melanoma	0.000549	0.00196	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Bleomycin—melanoma	0.000548	0.00196	CcSEcCtD
Naltrexone—Myalgia—Carmustine—melanoma	0.000548	0.00196	CcSEcCtD
Naltrexone—Chest pain—Carmustine—melanoma	0.000548	0.00196	CcSEcCtD
Naltrexone—Anxiety—Carmustine—melanoma	0.000546	0.00195	CcSEcCtD
Naltrexone—Cough—Temozolomide—melanoma	0.000543	0.00194	CcSEcCtD
Naltrexone—Paraesthesia—Bleomycin—melanoma	0.00054	0.00193	CcSEcCtD
Naltrexone—Weight increased—Docetaxel—melanoma	0.00054	0.00193	CcSEcCtD
Naltrexone—Convulsion—Temozolomide—melanoma	0.000539	0.00193	CcSEcCtD
Naltrexone—Weight decreased—Docetaxel—melanoma	0.000537	0.00192	CcSEcCtD
Naltrexone—Hypertension—Temozolomide—melanoma	0.000537	0.00192	CcSEcCtD
Naltrexone—Dyspnoea—Bleomycin—melanoma	0.000536	0.00192	CcSEcCtD
Naltrexone—Anorexia—Dactinomycin—melanoma	0.000535	0.00191	CcSEcCtD
Naltrexone—Pneumonia—Docetaxel—melanoma	0.000532	0.0019	CcSEcCtD
Naltrexone—Confusional state—Carmustine—melanoma	0.000529	0.00189	CcSEcCtD
Naltrexone—Arthralgia—Temozolomide—melanoma	0.000529	0.00189	CcSEcCtD
Naltrexone—Myalgia—Temozolomide—melanoma	0.000529	0.00189	CcSEcCtD
Naltrexone—Infestation NOS—Docetaxel—melanoma	0.000529	0.00189	CcSEcCtD
Naltrexone—Infestation—Docetaxel—melanoma	0.000529	0.00189	CcSEcCtD
Naltrexone—Anxiety—Temozolomide—melanoma	0.000528	0.00189	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.000526	0.00188	CcSEcCtD
Naltrexone—Oedema—Carmustine—melanoma	0.000525	0.00188	CcSEcCtD
Naltrexone—Discomfort—Temozolomide—melanoma	0.000523	0.00187	CcSEcCtD
Naltrexone—Decreased appetite—Bleomycin—melanoma	0.000523	0.00187	CcSEcCtD
Naltrexone—Infection—Carmustine—melanoma	0.000522	0.00186	CcSEcCtD
Naltrexone—Acute coronary syndrome—Docetaxel—melanoma	0.000522	0.00186	CcSEcCtD
Naltrexone—Myocardial infarction—Docetaxel—melanoma	0.000519	0.00185	CcSEcCtD
Naltrexone—Dry mouth—Temozolomide—melanoma	0.000518	0.00185	CcSEcCtD
Naltrexone—Pain—Bleomycin—melanoma	0.000514	0.00184	CcSEcCtD
Naltrexone—Conjunctivitis—Docetaxel—melanoma	0.000514	0.00184	CcSEcCtD
Naltrexone—Tachycardia—Carmustine—melanoma	0.000513	0.00183	CcSEcCtD
Naltrexone—Confusional state—Temozolomide—melanoma	0.000512	0.00183	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Dactinomycin—melanoma	0.000511	0.00183	CcSEcCtD
Naltrexone—Anaphylactic shock—Temozolomide—melanoma	0.000507	0.00181	CcSEcCtD
Naltrexone—Oedema—Temozolomide—melanoma	0.000507	0.00181	CcSEcCtD
Naltrexone—Infection—Temozolomide—melanoma	0.000504	0.0018	CcSEcCtD
Naltrexone—Anorexia—Carmustine—melanoma	0.000501	0.00179	CcSEcCtD
Naltrexone—Hepatobiliary disease—Docetaxel—melanoma	0.0005	0.00179	CcSEcCtD
Naltrexone—Epistaxis—Docetaxel—melanoma	0.000499	0.00178	CcSEcCtD
Naltrexone—Nervous system disorder—Temozolomide—melanoma	0.000498	0.00178	CcSEcCtD
Naltrexone—Feeling abnormal—Bleomycin—melanoma	0.000496	0.00177	CcSEcCtD
Naltrexone—Skin disorder—Temozolomide—melanoma	0.000493	0.00176	CcSEcCtD
Naltrexone—Hyperhidrosis—Temozolomide—melanoma	0.000491	0.00175	CcSEcCtD
Naltrexone—Decreased appetite—Dactinomycin—melanoma	0.000488	0.00174	CcSEcCtD
Naltrexone—Naloxone—ALB—melanoma	0.000486	0.0853	CrCbGaD
Naltrexone—Fatigue—Dactinomycin—melanoma	0.000484	0.00173	CcSEcCtD
Naltrexone—Anorexia—Temozolomide—melanoma	0.000484	0.00173	CcSEcCtD
Naltrexone—Pain—Dactinomycin—melanoma	0.00048	0.00172	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Carmustine—melanoma	0.000478	0.00171	CcSEcCtD
Naltrexone—Urticaria—Bleomycin—melanoma	0.000478	0.00171	CcSEcCtD
Naltrexone—Body temperature increased—Bleomycin—melanoma	0.000476	0.0017	CcSEcCtD
Naltrexone—Hepatitis—Docetaxel—melanoma	0.000475	0.0017	CcSEcCtD
Naltrexone—Insomnia—Carmustine—melanoma	0.000475	0.0017	CcSEcCtD
Naltrexone—Paraesthesia—Carmustine—melanoma	0.000472	0.00169	CcSEcCtD
Naltrexone—Pharyngitis—Docetaxel—melanoma	0.000471	0.00169	CcSEcCtD
Naltrexone—Dyspnoea—Carmustine—melanoma	0.000468	0.00167	CcSEcCtD
Naltrexone—Somnolence—Carmustine—melanoma	0.000467	0.00167	CcSEcCtD
Naltrexone—Buprenorphine—ABCB1—melanoma	0.000467	0.082	CrCbGaD
Naltrexone—Connective tissue disorder—Docetaxel—melanoma	0.000467	0.00167	CcSEcCtD
Naltrexone—Naloxone—ABCB1—melanoma	0.000463	0.0814	CrCbGaD
Naltrexone—Feeling abnormal—Dactinomycin—melanoma	0.000462	0.00165	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Temozolomide—melanoma	0.000462	0.00165	CcSEcCtD
Naltrexone—Insomnia—Temozolomide—melanoma	0.000459	0.00164	CcSEcCtD
Naltrexone—Gastrointestinal pain—Dactinomycin—melanoma	0.000459	0.00164	CcSEcCtD
Naltrexone—Decreased appetite—Carmustine—melanoma	0.000456	0.00163	CcSEcCtD
Naltrexone—Paraesthesia—Temozolomide—melanoma	0.000456	0.00163	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Carmustine—melanoma	0.000453	0.00162	CcSEcCtD
Naltrexone—Dyspnoea—Temozolomide—melanoma	0.000452	0.00162	CcSEcCtD
Naltrexone—Somnolence—Temozolomide—melanoma	0.000451	0.00161	CcSEcCtD
Naltrexone—Constipation—Carmustine—melanoma	0.000449	0.00161	CcSEcCtD
Naltrexone—Pain—Carmustine—melanoma	0.000449	0.00161	CcSEcCtD
Naltrexone—Eye disorder—Docetaxel—melanoma	0.000444	0.00159	CcSEcCtD
Naltrexone—Body temperature increased—Dactinomycin—melanoma	0.000444	0.00159	CcSEcCtD
Naltrexone—Abdominal pain—Dactinomycin—melanoma	0.000444	0.00159	CcSEcCtD
Naltrexone—Hypersensitivity—Bleomycin—melanoma	0.000443	0.00158	CcSEcCtD
Naltrexone—Decreased appetite—Temozolomide—melanoma	0.000441	0.00158	CcSEcCtD
Naltrexone—Cardiac disorder—Docetaxel—melanoma	0.000441	0.00158	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Temozolomide—melanoma	0.000438	0.00157	CcSEcCtD
Naltrexone—Fatigue—Temozolomide—melanoma	0.000438	0.00156	CcSEcCtD
Naltrexone—Constipation—Temozolomide—melanoma	0.000434	0.00155	CcSEcCtD
Naltrexone—Pain—Temozolomide—melanoma	0.000434	0.00155	CcSEcCtD
Naltrexone—Feeling abnormal—Carmustine—melanoma	0.000433	0.00155	CcSEcCtD
Naltrexone—Asthenia—Bleomycin—melanoma	0.000432	0.00154	CcSEcCtD
Naltrexone—Angiopathy—Docetaxel—melanoma	0.000431	0.00154	CcSEcCtD
Naltrexone—Gastrointestinal pain—Carmustine—melanoma	0.000429	0.00154	CcSEcCtD
Naltrexone—Immune system disorder—Docetaxel—melanoma	0.000429	0.00153	CcSEcCtD
Naltrexone—Mediastinal disorder—Docetaxel—melanoma	0.000428	0.00153	CcSEcCtD
Naltrexone—Chills—Docetaxel—melanoma	0.000426	0.00152	CcSEcCtD
Naltrexone—Pruritus—Bleomycin—melanoma	0.000426	0.00152	CcSEcCtD
Naltrexone—Alopecia—Docetaxel—melanoma	0.00042	0.0015	CcSEcCtD
Naltrexone—Feeling abnormal—Temozolomide—melanoma	0.000418	0.00149	CcSEcCtD
Naltrexone—Mental disorder—Docetaxel—melanoma	0.000416	0.00149	CcSEcCtD
Naltrexone—Body temperature increased—Carmustine—melanoma	0.000415	0.00148	CcSEcCtD
Naltrexone—Abdominal pain—Carmustine—melanoma	0.000415	0.00148	CcSEcCtD
Naltrexone—Gastrointestinal pain—Temozolomide—melanoma	0.000415	0.00148	CcSEcCtD
Naltrexone—Malnutrition—Docetaxel—melanoma	0.000414	0.00148	CcSEcCtD
Naltrexone—Hypersensitivity—Dactinomycin—melanoma	0.000413	0.00148	CcSEcCtD
Naltrexone—Dysgeusia—Docetaxel—melanoma	0.000405	0.00145	CcSEcCtD
Naltrexone—Urticaria—Temozolomide—melanoma	0.000403	0.00144	CcSEcCtD
Naltrexone—Asthenia—Dactinomycin—melanoma	0.000403	0.00144	CcSEcCtD
Naltrexone—Abdominal pain—Temozolomide—melanoma	0.000401	0.00143	CcSEcCtD
Naltrexone—Body temperature increased—Temozolomide—melanoma	0.000401	0.00143	CcSEcCtD
Naltrexone—Back pain—Docetaxel—melanoma	0.0004	0.00143	CcSEcCtD
Naltrexone—Muscle spasms—Docetaxel—melanoma	0.000398	0.00142	CcSEcCtD
Naltrexone—Morphine—ABCB1—melanoma	0.000391	0.0687	CrCbGaD
Naltrexone—Hypersensitivity—Carmustine—melanoma	0.000387	0.00138	CcSEcCtD
Naltrexone—Diarrhoea—Dactinomycin—melanoma	0.000384	0.00137	CcSEcCtD
Naltrexone—Vomiting—Bleomycin—melanoma	0.000383	0.00137	CcSEcCtD
Naltrexone—Rash—Bleomycin—melanoma	0.000379	0.00136	CcSEcCtD
Naltrexone—Dermatitis—Bleomycin—melanoma	0.000379	0.00135	CcSEcCtD
Naltrexone—Asthenia—Carmustine—melanoma	0.000377	0.00135	CcSEcCtD
Naltrexone—Hypersensitivity—Temozolomide—melanoma	0.000374	0.00134	CcSEcCtD
Naltrexone—Syncope—Docetaxel—melanoma	0.000371	0.00133	CcSEcCtD
Naltrexone—Palpitations—Docetaxel—melanoma	0.000365	0.00131	CcSEcCtD
Naltrexone—Asthenia—Temozolomide—melanoma	0.000364	0.0013	CcSEcCtD
Naltrexone—Loss of consciousness—Docetaxel—melanoma	0.000363	0.0013	CcSEcCtD
Naltrexone—Cough—Docetaxel—melanoma	0.000361	0.00129	CcSEcCtD
Naltrexone—Diarrhoea—Carmustine—melanoma	0.000359	0.00128	CcSEcCtD
Naltrexone—Pruritus—Temozolomide—melanoma	0.000359	0.00128	CcSEcCtD
Naltrexone—Convulsion—Docetaxel—melanoma	0.000358	0.00128	CcSEcCtD
Naltrexone—Nausea—Bleomycin—melanoma	0.000357	0.00128	CcSEcCtD
Naltrexone—Hypertension—Docetaxel—melanoma	0.000357	0.00128	CcSEcCtD
Naltrexone—Vomiting—Dactinomycin—melanoma	0.000357	0.00128	CcSEcCtD
Naltrexone—Rash—Dactinomycin—melanoma	0.000354	0.00126	CcSEcCtD
Naltrexone—Arthralgia—Docetaxel—melanoma	0.000352	0.00126	CcSEcCtD
Naltrexone—Chest pain—Docetaxel—melanoma	0.000352	0.00126	CcSEcCtD
Naltrexone—Myalgia—Docetaxel—melanoma	0.000352	0.00126	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.00035	0.00125	CcSEcCtD
Naltrexone—Dizziness—Carmustine—melanoma	0.000347	0.00124	CcSEcCtD
Naltrexone—Diarrhoea—Temozolomide—melanoma	0.000347	0.00124	CcSEcCtD
Naltrexone—Dry mouth—Docetaxel—melanoma	0.000344	0.00123	CcSEcCtD
Naltrexone—Confusional state—Docetaxel—melanoma	0.00034	0.00122	CcSEcCtD
Naltrexone—Oedema—Docetaxel—melanoma	0.000337	0.00121	CcSEcCtD
Naltrexone—Anaphylactic shock—Docetaxel—melanoma	0.000337	0.00121	CcSEcCtD
Naltrexone—Dizziness—Temozolomide—melanoma	0.000336	0.0012	CcSEcCtD
Naltrexone—Infection—Docetaxel—melanoma	0.000335	0.0012	CcSEcCtD
Naltrexone—Vomiting—Carmustine—melanoma	0.000334	0.00119	CcSEcCtD
Naltrexone—Nausea—Dactinomycin—melanoma	0.000333	0.00119	CcSEcCtD
Naltrexone—Shock—Docetaxel—melanoma	0.000332	0.00119	CcSEcCtD
Naltrexone—Rash—Carmustine—melanoma	0.000331	0.00118	CcSEcCtD
Naltrexone—Nervous system disorder—Docetaxel—melanoma	0.000331	0.00118	CcSEcCtD
Naltrexone—Dermatitis—Carmustine—melanoma	0.000331	0.00118	CcSEcCtD
Naltrexone—Tachycardia—Docetaxel—melanoma	0.000329	0.00118	CcSEcCtD
Naltrexone—Headache—Carmustine—melanoma	0.000329	0.00118	CcSEcCtD
Naltrexone—Skin disorder—Docetaxel—melanoma	0.000328	0.00117	CcSEcCtD
Naltrexone—Vomiting—Temozolomide—melanoma	0.000323	0.00115	CcSEcCtD
Naltrexone—Anorexia—Docetaxel—melanoma	0.000322	0.00115	CcSEcCtD
Naltrexone—Rash—Temozolomide—melanoma	0.00032	0.00114	CcSEcCtD
Naltrexone—Dermatitis—Temozolomide—melanoma	0.00032	0.00114	CcSEcCtD
Naltrexone—Headache—Temozolomide—melanoma	0.000318	0.00114	CcSEcCtD
Naltrexone—Nausea—Carmustine—melanoma	0.000312	0.00112	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Docetaxel—melanoma	0.000307	0.0011	CcSEcCtD
Naltrexone—Insomnia—Docetaxel—melanoma	0.000305	0.00109	CcSEcCtD
Naltrexone—Paraesthesia—Docetaxel—melanoma	0.000303	0.00108	CcSEcCtD
Naltrexone—Nausea—Temozolomide—melanoma	0.000301	0.00108	CcSEcCtD
Naltrexone—Dyspnoea—Docetaxel—melanoma	0.000301	0.00108	CcSEcCtD
Naltrexone—Somnolence—Docetaxel—melanoma	0.0003	0.00107	CcSEcCtD
Naltrexone—Decreased appetite—Docetaxel—melanoma	0.000293	0.00105	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Docetaxel—melanoma	0.000291	0.00104	CcSEcCtD
Naltrexone—Fatigue—Docetaxel—melanoma	0.000291	0.00104	CcSEcCtD
Naltrexone—Pain—Docetaxel—melanoma	0.000289	0.00103	CcSEcCtD
Naltrexone—Constipation—Docetaxel—melanoma	0.000289	0.00103	CcSEcCtD
Naltrexone—Feeling abnormal—Docetaxel—melanoma	0.000278	0.000994	CcSEcCtD
Naltrexone—Gastrointestinal pain—Docetaxel—melanoma	0.000276	0.000987	CcSEcCtD
Naltrexone—Abdominal pain—Docetaxel—melanoma	0.000267	0.000954	CcSEcCtD
Naltrexone—Body temperature increased—Docetaxel—melanoma	0.000267	0.000954	CcSEcCtD
Naltrexone—Hypersensitivity—Docetaxel—melanoma	0.000249	0.000889	CcSEcCtD
Naltrexone—Asthenia—Docetaxel—melanoma	0.000242	0.000866	CcSEcCtD
Naltrexone—Pruritus—Docetaxel—melanoma	0.000239	0.000854	CcSEcCtD
Naltrexone—Diarrhoea—Docetaxel—melanoma	0.000231	0.000825	CcSEcCtD
Naltrexone—Dizziness—Docetaxel—melanoma	0.000223	0.000798	CcSEcCtD
Naltrexone—Vomiting—Docetaxel—melanoma	0.000215	0.000767	CcSEcCtD
Naltrexone—Rash—Docetaxel—melanoma	0.000213	0.000761	CcSEcCtD
Naltrexone—Dermatitis—Docetaxel—melanoma	0.000213	0.00076	CcSEcCtD
Naltrexone—Headache—Docetaxel—melanoma	0.000211	0.000756	CcSEcCtD
Naltrexone—Nausea—Docetaxel—melanoma	0.0002	0.000717	CcSEcCtD
Naltrexone—UGT1A1—Metabolism—ABCB1—melanoma	3.96e-05	0.000228	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—ERBB4—melanoma	3.96e-05	0.000228	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—PIK3CG—melanoma	3.95e-05	0.000227	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—PIK3CB—melanoma	3.95e-05	0.000227	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—SPP1—melanoma	3.94e-05	0.000227	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MAP2K2—melanoma	3.93e-05	0.000226	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—CXCL8—melanoma	3.93e-05	0.000226	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CDKN2B—melanoma	3.92e-05	0.000226	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—melanoma	3.88e-05	0.000223	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—SYK—melanoma	3.86e-05	0.000222	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—PIK3CD—melanoma	3.83e-05	0.00022	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CD86—melanoma	3.79e-05	0.000218	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—CXCL8—melanoma	3.79e-05	0.000218	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—melanoma	3.79e-05	0.000218	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—melanoma	3.79e-05	0.000218	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ITGAV—melanoma	3.79e-05	0.000218	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NGFR—melanoma	3.79e-05	0.000218	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—AKT3—melanoma	3.79e-05	0.000218	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—EDN1—melanoma	3.76e-05	0.000216	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—IL2—melanoma	3.75e-05	0.000216	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—TERT—melanoma	3.74e-05	0.000215	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—RAC1—melanoma	3.73e-05	0.000214	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—FGF1—melanoma	3.68e-05	0.000212	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CSF2—melanoma	3.68e-05	0.000212	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PRKCA—melanoma	3.65e-05	0.00021	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—IL2—melanoma	3.62e-05	0.000208	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—ERCC2—melanoma	3.62e-05	0.000208	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—melanoma	3.61e-05	0.000208	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—E2F1—melanoma	3.6e-05	0.000207	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—PIK3CB—melanoma	3.58e-05	0.000206	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—melanoma	3.58e-05	0.000206	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—HIF1A—melanoma	3.58e-05	0.000206	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PDGFRA—melanoma	3.56e-05	0.000205	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PRKCA—melanoma	3.53e-05	0.000203	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—ITGB3—melanoma	3.53e-05	0.000203	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—SOCS1—melanoma	3.51e-05	0.000202	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—MAP2K1—melanoma	3.5e-05	0.000201	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—S100B—melanoma	3.5e-05	0.000201	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—PIK3CD—melanoma	3.47e-05	0.0002	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PLA2G6—melanoma	3.46e-05	0.000199	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—SPP1—melanoma	3.46e-05	0.000199	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MAP2K2—melanoma	3.45e-05	0.000198	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—CXCL8—melanoma	3.44e-05	0.000198	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—KDR—melanoma	3.42e-05	0.000197	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ERBB4—melanoma	3.34e-05	0.000192	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—PIK3CB—melanoma	3.34e-05	0.000192	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CDKN2B—melanoma	3.32e-05	0.000191	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—FN1—melanoma	3.29e-05	0.000189	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—IL2—melanoma	3.29e-05	0.000189	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—melanoma	3.29e-05	0.000189	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—TERT—melanoma	3.28e-05	0.000189	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—RAC1—melanoma	3.27e-05	0.000188	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—NOTCH1—melanoma	3.22e-05	0.000185	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CD86—melanoma	3.21e-05	0.000184	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—CXCL8—melanoma	3.21e-05	0.000184	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—melanoma	3.18e-05	0.000183	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—EDN1—melanoma	3.18e-05	0.000183	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CD80—melanoma	3.16e-05	0.000182	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PIK3CG—melanoma	3.15e-05	0.000181	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—KIT—melanoma	3.15e-05	0.000181	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—APC—melanoma	3.15e-05	0.000181	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—NRAS—melanoma	3.15e-05	0.000181	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—HIF1A—melanoma	3.14e-05	0.00018	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—EGF—melanoma	3.11e-05	0.000179	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—FGF1—melanoma	3.11e-05	0.000179	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CSF2—melanoma	3.11e-05	0.000179	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—VCAN—melanoma	3.11e-05	0.000179	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—IL2—melanoma	3.06e-05	0.000176	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—E2F1—melanoma	3.04e-05	0.000175	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—PIK3CB—melanoma	3.03e-05	0.000174	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—MAPK3—melanoma	3.02e-05	0.000174	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PDGFRA—melanoma	3.01e-05	0.000173	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—KDR—melanoma	3e-05	0.000172	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ITGB3—melanoma	2.98e-05	0.000171	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PRKCA—melanoma	2.98e-05	0.000171	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—BRAF—melanoma	2.96e-05	0.00017	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—SPP1—melanoma	2.92e-05	0.000168	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MAP2K2—melanoma	2.91e-05	0.000168	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CXCL8—melanoma	2.91e-05	0.000167	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—FN1—melanoma	2.89e-05	0.000166	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IGF1—melanoma	2.88e-05	0.000166	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—MAPK1—melanoma	2.87e-05	0.000165	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—EGFR—melanoma	2.87e-05	0.000165	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PIK3CG—melanoma	2.86e-05	0.000164	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NOTCH1—melanoma	2.83e-05	0.000162	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MAP2K1—melanoma	2.79e-05	0.00016	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—IL2—melanoma	2.78e-05	0.00016	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TERT—melanoma	2.77e-05	0.000159	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PIK3CD—melanoma	2.77e-05	0.000159	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CD80—melanoma	2.77e-05	0.000159	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—RAC1—melanoma	2.76e-05	0.000159	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—KIT—melanoma	2.76e-05	0.000159	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—APC—melanoma	2.76e-05	0.000159	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PIK3CG—melanoma	2.76e-05	0.000159	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—NRAS—melanoma	2.76e-05	0.000159	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PPARG—melanoma	2.76e-05	0.000158	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—PIK3CA—melanoma	2.74e-05	0.000158	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—EGF—melanoma	2.73e-05	0.000157	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—KRAS—melanoma	2.71e-05	0.000156	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—melanoma	2.69e-05	0.000155	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—FGF2—melanoma	2.65e-05	0.000153	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—HIF1A—melanoma	2.65e-05	0.000152	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—MAPK3—melanoma	2.65e-05	0.000152	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CYP17A1—melanoma	2.62e-05	0.000151	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—BRAF—melanoma	2.6e-05	0.000149	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—KDR—melanoma	2.53e-05	0.000146	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IGF1—melanoma	2.53e-05	0.000145	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—MAPK1—melanoma	2.52e-05	0.000145	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—EGFR—melanoma	2.52e-05	0.000145	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PIK3CD—melanoma	2.51e-05	0.000144	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—PIK3CA—melanoma	2.49e-05	0.000143	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MDM2—melanoma	2.48e-05	0.000143	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—ALB—melanoma	2.48e-05	0.000143	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GNA11—melanoma	2.48e-05	0.000142	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—ERBB2—melanoma	2.45e-05	0.000141	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MAP2K1—melanoma	2.44e-05	0.000141	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—FN1—melanoma	2.44e-05	0.00014	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PIK3CD—melanoma	2.43e-05	0.00014	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—ALB—melanoma	2.43e-05	0.00014	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—FASN—melanoma	2.42e-05	0.000139	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PIK3CB—melanoma	2.41e-05	0.000139	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—PIK3CA—melanoma	2.41e-05	0.000138	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NOTCH1—melanoma	2.39e-05	0.000137	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—SLC5A5—melanoma	2.38e-05	0.000137	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—KRAS—melanoma	2.38e-05	0.000137	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CD80—melanoma	2.34e-05	0.000135	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—KIT—melanoma	2.33e-05	0.000134	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—APC—melanoma	2.33e-05	0.000134	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PIK3CG—melanoma	2.33e-05	0.000134	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—NRAS—melanoma	2.33e-05	0.000134	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—FGF2—melanoma	2.33e-05	0.000134	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CXCL8—melanoma	2.32e-05	0.000133	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—EGF—melanoma	2.31e-05	0.000133	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—HRAS—melanoma	2.3e-05	0.000133	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GNAQ—melanoma	2.3e-05	0.000132	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CD44—melanoma	2.3e-05	0.000132	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CDKN1B—melanoma	2.27e-05	0.00013	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—AKT1—melanoma	2.24e-05	0.000129	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—MAPK3—melanoma	2.24e-05	0.000129	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CASP3—melanoma	2.22e-05	0.000128	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IL2—melanoma	2.22e-05	0.000128	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CYP1B1—melanoma	2.21e-05	0.000127	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—IL6—melanoma	2.21e-05	0.000127	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—BRAF—melanoma	2.19e-05	0.000126	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PIK3CB—melanoma	2.19e-05	0.000126	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—PIK3CA—melanoma	2.18e-05	0.000126	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MDM2—melanoma	2.18e-05	0.000125	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PTGS2—melanoma	2.17e-05	0.000125	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CCND1—melanoma	2.16e-05	0.000124	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—ERBB2—melanoma	2.15e-05	0.000123	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CTNNB1—melanoma	2.14e-05	0.000123	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IGF1—melanoma	2.14e-05	0.000123	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—MAPK1—melanoma	2.13e-05	0.000122	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—EGFR—melanoma	2.13e-05	0.000122	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PIK3CB—melanoma	2.12e-05	0.000122	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MMP9—melanoma	2.1e-05	0.000121	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CDKN1A—melanoma	2.09e-05	0.00012	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PTEN—melanoma	2.09e-05	0.00012	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—NFKB1—melanoma	2.08e-05	0.000119	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MAP2K1—melanoma	2.07e-05	0.000119	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PIK3CD—melanoma	2.05e-05	0.000118	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—AKT1—melanoma	2.04e-05	0.000117	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CXCL8—melanoma	2.03e-05	0.000117	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—PIK3CA—melanoma	2.03e-05	0.000117	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—HRAS—melanoma	2.02e-05	0.000116	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—KRAS—melanoma	2.01e-05	0.000116	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CDKN1B—melanoma	1.99e-05	0.000114	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—FGF2—melanoma	1.97e-05	0.000113	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—AKT1—melanoma	1.97e-05	0.000113	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CASP3—melanoma	1.95e-05	0.000112	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IL2—melanoma	1.94e-05	0.000112	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—IL6—melanoma	1.93e-05	0.000111	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CCND1—melanoma	1.9e-05	0.000109	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PTEN—melanoma	1.89e-05	0.000109	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—VEGFA—melanoma	1.88e-05	0.000108	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CTNNB1—melanoma	1.88e-05	0.000108	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—STAT3—melanoma	1.87e-05	0.000107	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—NRAS—melanoma	1.86e-05	0.000107	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—PIK3CA—melanoma	1.85e-05	0.000106	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MMP9—melanoma	1.84e-05	0.000106	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MDM2—melanoma	1.84e-05	0.000106	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CDKN1A—melanoma	1.83e-05	0.000105	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PTEN—melanoma	1.83e-05	0.000105	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NFKB1—melanoma	1.82e-05	0.000105	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ERBB2—melanoma	1.81e-05	0.000104	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PIK3CB—melanoma	1.79e-05	0.000103	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—AKT1—melanoma	1.78e-05	0.000103	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MAPK3—melanoma	1.78e-05	0.000103	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MYC—melanoma	1.73e-05	9.97e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CXCL8—melanoma	1.72e-05	9.89e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—HRAS—melanoma	1.71e-05	9.82e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MAPK1—melanoma	1.7e-05	9.75e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—EGFR—melanoma	1.7e-05	9.75e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CDKN1B—melanoma	1.68e-05	9.66e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PRKCA—melanoma	1.67e-05	9.62e-05	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—AKT1—melanoma	1.66e-05	9.55e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ERCC2—melanoma	1.66e-05	9.54e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—VEGFA—melanoma	1.65e-05	9.5e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CASP3—melanoma	1.65e-05	9.46e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IL2—melanoma	1.64e-05	9.45e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—STAT3—melanoma	1.64e-05	9.41e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—IL6—melanoma	1.63e-05	9.4e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NRAS—melanoma	1.63e-05	9.39e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—KRAS—melanoma	1.6e-05	9.21e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CCND1—melanoma	1.6e-05	9.21e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CTNNB1—melanoma	1.59e-05	9.12e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MAPK3—melanoma	1.56e-05	8.99e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MMP9—melanoma	1.56e-05	8.94e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CDKN1A—melanoma	1.55e-05	8.91e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PTEN—melanoma	1.55e-05	8.89e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NFKB1—melanoma	1.54e-05	8.85e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MYC—melanoma	1.52e-05	8.74e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—AKT1—melanoma	1.51e-05	8.67e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MAPK1—melanoma	1.49e-05	8.55e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—EGFR—melanoma	1.49e-05	8.55e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PIK3CA—melanoma	1.47e-05	8.46e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—TP53—melanoma	1.42e-05	8.19e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—KRAS—melanoma	1.4e-05	8.08e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—VEGFA—melanoma	1.4e-05	8.03e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—STAT3—melanoma	1.38e-05	7.95e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NRAS—melanoma	1.38e-05	7.93e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—HRAS—melanoma	1.36e-05	7.83e-05	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PIK3CA—melanoma	1.33e-05	7.67e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MAPK3—melanoma	1.32e-05	7.6e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PIK3CG—melanoma	1.31e-05	7.53e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IL6—melanoma	1.3e-05	7.49e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PIK3CA—melanoma	1.29e-05	7.42e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MYC—melanoma	1.28e-05	7.39e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PPARG—melanoma	1.26e-05	7.27e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MAPK1—melanoma	1.26e-05	7.23e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—EGFR—melanoma	1.26e-05	7.23e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—TP53—melanoma	1.25e-05	7.18e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—AKT1—melanoma	1.2e-05	6.91e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—HRAS—melanoma	1.19e-05	6.87e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—KRAS—melanoma	1.19e-05	6.83e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PIK3CD—melanoma	1.15e-05	6.62e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IL6—melanoma	1.14e-05	6.57e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ALB—melanoma	1.14e-05	6.54e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PIK3CA—melanoma	1.09e-05	6.27e-05	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—AKT1—melanoma	1.09e-05	6.27e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TP53—melanoma	1.06e-05	6.07e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—AKT1—melanoma	1.05e-05	6.06e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—HRAS—melanoma	1.01e-05	5.8e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PIK3CB—melanoma	1e-05	5.77e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PTGS2—melanoma	9.95e-06	5.72e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IL6—melanoma	9.66e-06	5.55e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—AKT1—melanoma	8.91e-06	5.12e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PTEN—melanoma	8.67e-06	4.99e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PIK3CA—melanoma	6.12e-06	3.52e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—AKT1—melanoma	5e-06	2.87e-05	CbGpPWpGaD
